Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Knee surgery pain relief gets a precision upgrade: new trial tests optimal dose

NCT ID NCT06942689

Symptom relief Sponsor: Nanjing First Hospital, Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 11, 2026 · Updated 4 times

Summary

This study tests different volumes of liposomal bupivacaine, a long-acting painkiller, injected near the nerve in the thigh to numb the knee during surgery. The goal is to find the dose that provides good pain control while minimizing leg muscle weakness. Sixty-three adults having knee surgery will receive one of several volumes, and researchers will measure pain scores and muscle strength. The results could lead to more personalized and effective pain management after knee procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liposomal bupivacaine
What this could lead to
If successful, this could provide a precise dosing guide for longer-lasting pain relief after knee surgery with less muscle weakness.
What could go wrong
This is a small, early-phase trial (63 people) focused on dosing, not on proving long-term benefits. The results may not apply to all patients or surgeries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing elective general anesthesia for unilateral knee joint surgery. * Patients who provide informed consent. * Aged between 18 and 65 years old, regardless of gender. * American Society of Anesthesiologists (ASA) physical status classification of Ⅰ to Ⅲ * Body mass index (BMI) ≤ 35 kg/m². Exclusion Criteria: * Femoral neuropathy. * Coagulation dysfunction. * Allergy to local anesthetics. * Infection at the puncture site. * History of chronic pain or opioid use. * Pregnancy. * Diabetes mellitus and peripheral neuropathy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Optimal volume of liposomal bupivacaine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Optimal volume of liposomal bupivacaine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nanjing First Hospital

    RECRUITING

    Nanjing, Jiangsu, 210006, China